Chemokine initiated by Jennings at speculative buy

Chemokine Therapeutics Corp. was initiated by Jennings Capital Inc. with a speculative buy rating. Vancouver, B.C.-based Chemokine is developing peptide-based therapies to treat cancer, blood disorders, cardiovascular and infectious diseases. Jennings has a C$2 target on the stock. On the Toronto exchange, Chemokine shares on Thursday lost C$0.02, or 2%, to close at C$0.98 on volume of 6,000 shares versus the three-month running average of 48,344.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.